The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer

CME Activity Information
Release Date:	January 16, 2007
Most Recent Review:	January 16, 2007*
Most Recent Update:	January 16, 2007
Date Credit Expires:	January 16, 2009
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by January 16, 2009, in order to receive the credit or participation certificate.

1. Discuss recent progress in the treatment of patients with advanced colorectal cancer.
2. Define the continuum of care approach and how it may differ from our current approach to the treatment of patients with advanced colorectal cancer.
3. Identify key factors in treatment selection for patients with advanced colorectal cancer.
4. Explain the impact of each active drug in the treatment of advanced colorectal cancer and the impact of treatment with multiple agents over the course of the disease.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Pfizer's irinotecan, sanofi-aventis's oxaliplatin, Bristol-Myers Squibb's cetuximab, Genentech's bevacizumab, and Roche's capecitabine for advanced disease. The author has also been a consultant for Pfizer's irinotecan, sanofi-aventis's oxaliplatin, Bristol-Myers Squibb's cetuximab, and Genentech's bevacizumab.

Mace L. Rothenberg, M.D.

Credentials: Division of Hematology/Medical Oncology, Vanderbilt University, Nashville, Tennessee, USA. Telephone: 615-936-1796; Fax: 615-343-7602; E-mail: mace.rothenberg{at}vanderbilt.edu.
Disclosures: The author has been a consultant and received research support for Pfizer's irinotecan, sanofi-aventis's oxaliplatin, ImClone's cetuximab, and Roche's capecitabine.

Eric Van Cutsem, M.D., Ph.D.

Credentials: Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
Disclosures: The author has received research funding for Pfizer's irinotecan and sanofi-aventis's oxaliplatin.

Al B. Benson, III, M.D., F.A.C.P.

Credentials: Division of Hematology/Oncology, Northwestern University, Chicago, Illinois, USA.
Disclosures: The author has indicated that that they discuss the unlabeled, investigational, or alternative use(s) of Amgen's panitumumab, Bristol-Myers Squibb's cetuximab, Genentech's bevacizumab, ImClone's cetuximab, Pfizer's irinotecan, Roche's capecitabine, and sanofi-aventis's oxaliplatin for colorectal cancer. The author has also indicated that he has a relationship with the above mentioned companies and products.

Charles D. Blanke, M.D.

Credentials: Oregon Health & Science University Cancer Institute, Portland, Oregon, USA.
Disclosures: The author has indicated no relevant commercial relationships.

Robert B. Diasio, M.D.

Credentials: Division of Hematology/Oncology, University of Alabama School of Medicine, Birmingham, Alabama, USA.
Disclosures: The author has been a consultant for Bristol-Myers Squibb's Erbitux, sanofi-aventis's oxaliplatin, Genentech's Avastin, Pfizer's irinotecan, and Roche's capecitabine.

Axel Grothey, M.D.

Credentials: Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Disclosures: The author has received financial support for work related to sanofi-aventis's oxaliplatin and Bristol-Myers Squibb's cetuximab.

Heinz-Josef Lenz, M.D.

Credentials: Division of Medical Oncology, University of Southern California, Los Angeles, California, USA.
Disclosures: The author has received support and has worked as a consultant and speaker for Bristol-Myers Squibb's Erbitux and sanofi-aventis's oxaliplatin.

Neal J. Meropol, M.D.

Credentials: Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Disclosures: The author has worked as a consultant for Pfizer's irinotecan and Amgen's panitumumab. The author has worked as a consultant and received research support for Genentech's bevacizumab.

Ramesh K. Ramanathan, M.D.

Credentials: Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of ImClone's cetuximab, Amgen's panitumamab, Roche's capecitabine, sanofi-aventis's oxaliplatin, Pfizer's irinotecan, and Genentech's bevacizumab for new trials. The author has as served on the speaker's bureau for sanofi-aventis's oxaliplatin.

Carlos H. Roberto Becerra, M.D.

Credentials: Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Disclosures: The author has served on the speaker's bureau for sanofi-aventis's oxaliplatin.

Rita S. Wickham, Ph.D., R.N., A.O.C.N®, C.H.P.N.

Credentials: Department of Adult Health Nursing, Rush University Medical Center, Chicago, Illinois, USA.
Disclosures: The author has received financial support for work related to sanofi-aventis's Eloxatin.

Delma Armstrong, B.S.N., R.N., C.R.N.

Credentials: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Disclosures: The author has served on the Nurse Advisory Board for Pfizer's comptosar. The authos has also served as a speaker for Genomic Health, Inc.

Carol Viele, R.N., M.S.

Credentials: Department of Nursing at University of California San Francisco Medical Center, San Francisco, California, USA.
Disclosures: The author has served on the Speaker's Bureau for sanofi-aventis and Pfizer.

• Take this course